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OBJECTIVE: To investigate the transmission of anti-Staphylococcus aureus (Sa) IgG, IgG1 and IgG2 via placental
transfer and the transfer of IgA via the colostrum according to maternal Sa carrier status at delivery.
METHODS:We evaluated anti-Sa IgG, IgG1 and IgG2 in maternal and cord sera and IgA in colostrum from a case
(n=49, Sa+) and a control group (n=98, Sa-).
RESULTS: Of the 250 parturients analyzed for this study, 49 were nasally colonized with S. aureus (prevalence of
19.6%). Ninety-eight non-colonized subjects were selected for the control group. The anti-Sa IgG, IgG1 and
IgG2 levels and the IgG avidity indexes in the maternal and cord sera did not differ between the groups, with a
low transfer ratio of anti-Sa IgG to the newborns in both groups. The anti-Sa IgG2 titers were significantly
higher than the IgG1 titers in the maternal and cord sera. Inversely, the transfer ratios were higher for anti-Sa
IgG1 compared with IgG2; however, no differences between the groups were detected. The Sa-specific IgA
levels and avidity indexes in the colostrum were equivalent between groups.
CONCLUSIONS: Maternal Sa nasal colonization at delivery is not associated with higher antibody levels in the
mother or newborns. The high titers of anti-Sa IgG2 found in the cord serum indicate a greater reactivity with
non-protein antigens, which may further contribute to the susceptibility to staphylococcal infections at birth.
The presence of IgA in the colostrum with avidity to S. aureus reinforces the importance of breastfeeding
shortly after birth.
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’ INTRODUCTION
Staphylococcus aureus (S. aureus) is among the bacteria that
colonize the mucous membranes of pregnant women and,
soon after birth, their newborns (NB). In the neonatal period,
S. aureus has been associated with a variety of disorders of
varying degrees of severity, such as nosocomial outbreaks
of neonatal impetigo (1), omphalitis (2), arthritis and osteo-
myelitis (3), late neonatal nosocomial or community-
acquired sepsis (4,5), and sudden infant death syndrome (6).
A systematic review of the literature, with 19 studies and
more than 4000 blood culture isolates identified that the most
common causes of neonatal bacteremia were Staphylococcus
aureus, Escherichia coli and Klebsiella spp., which accounted for
55% of culture positive sepsis; and using a meta-analysis to
weight for study size, S. aureus isolates accounted for 26% of
bacterial sepsis cases among neonates (4).
Colonization studies of paired mothers and children
have shown that, from birth, children from mothers with an
S. aureus nasal carriage are more likely to be colonized by this
microorganism than children from non-colonized mothers,
with a high genomic concordance between the maternal and
newborn S. aureus strains (7,8).
S. aureus that passes across epithelial barriers undergoes
phagocytosis and bacterial killing, with a significant involve-
ment of neutrophils (9). Placental transfer of serum IgG and
IgA transmission in the colostrum from the mother to
her newborn may contribute to the processes of bacterial
neutralization and exclusion and the establishment of the
intestinal microbiota (10,11). Because newborn neutrophilsDOI: 10.6061/clinics/2016(12)02
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are characterized by lower chemotaxis, phagocytosis, and
oxidative burst responses (5) and the acquired immune
response is still being developed, the passive transfer of
maternal antibodies may improve the opsonophagocytic
capacity of newborns against S. aureus (6).
To gain a better understanding of the passive protection
provided by the mother, we investigated whether mothers
can provide S. aureus-specific antibodies to their infants
according to maternal nasal carrier status. Because the nature
of the antibody transmitted to the newborn, i.e., the pre-
dominant antibody subclass or antibody avidity, can inter-
fere with the effectiveness of placental transfer and newborn
protection, we evaluated the presence of anti-S. aureus
antibodies in the maternal and umbilical cord sera or the
colostrum and evaluated whether maternal carrier status
during delivery influenced the amount and nature of the
antibody.
’ MATERIALS AND METHODS
Study population
This was a cross-cohort study of paired parturients and
their term newborns with (n=49) and without (n=98) nasal
colonization by S. aureus. Two hundred and fifty mothers
were selected at two maternity wards in Cuiabá, Mato
Grosso, Brazil, during the period from August 2011 to
September 2012, according to the following inclusion criteria:
healthy mothers older than 20 years old with healthy term
newborns with an adequate weight for the gestational age
and a 5 minute Apgar score 47. The exclusion criteria
included placental malformation, chronic disease, severe
infectious disease either during pregnancy or during the
delivery period and a positive serology for conventional
serologic tests.
The samples were collected after informed consent and the
approval of the Ethics Committee of the University Hospital
(Protocol 936/CEP-HUJM/2010), the Research and Ethics
Committee of the Department of Pediatrics of São Paulo
University School of Medicine and the Ethics Committee for
the Analysis of Projects and Research of the Hospital das
Clínicas (Project 316/11). All of the guidelines for human
experimentation were followed.
Blood samples and nasal swabs were collected from the
mothers shortly before delivery, and the blood samples
were collected from the respective newborn umbilical cords
immediately after delivery from a large vein on the fetal side
of the placenta. The sera were separated, aliquoted and stored
at -80oC until use. The colostrum samples were collected
approximately 24 hours after delivery. The samples were
defatted by centrifugation, and the liquid phase was stored in
aliquots at -80oC.
Two control pools were used: a human serum pool pre-
pared with serum from healthy 18-40-year-old blood donors
with negative results for conventional serologic tests and a
human colostrum pool prepared with colostrum from healthy
mothers; both were already available in our laboratory.
S. aureus isolation and identification
Nasal swabs from all of the parturients were placed
in Stuart medium (Absorves CRAL, Cotia, SP, Brazil) for
transport and inoculated in mannitol salt agar for 24 hours at
35oC. The identification of S. aureus colony forming units
(CFUs) and antimicrobial susceptibility by minimal inhibi-
tory concentration (MIC) were performed by an auto-
mated method using Vitek 2 equipment (Biomerieuxs,
Marcy-l’Étoile, France). The S. aureus strain used in this study,
ISA35, was isolated from community with 99% identity with
S. aureus and defined as a methicillin-sensitive S. aureus (MSSA).
Total serum IgG and colostrum IgA determination
The total IgG concentrations were measured in the maternal
and umbilical cord serum using the immunoturbidimetry
technique. The results were expressed in mg/dL. The total
IgA antibodies present in the maternal colostrum were
measured by ELISA as previously described (12), and the
results were expressed in g/L.
Anti-S. aureus IgG and IgA determination
The anti-S. aureus (Sa) IgG concentrations in the maternal
and umbilical cord serum and the anti-Sa IgA concentrations
in the colostrum were determined by enzyme-linked immu-
nosorbent assays (ELISA) as described by Carbonare et al. (13)
with some modifications. In brief, an overnight culture of
S. aureus grown in BHI broth at 37oC was inactivated, centri-
fuged and resuspended in a 1% EDAC (N-(3-dimethyl-
aminopropyl)-N0-ethylcarbodiimide hydrochloride, Sigma,
St. Louis, MO, USA) solution in distilled water to an optical
density (OD) of 0.8 at 540 nm. An aliquot of 100 ml of this
suspension was used in each well for coating the microplates
(Costar, Cambridge, MA, USA), which were maintained for 16
to 18 hours at 37oC. After blocking with 1% non-fat milk, the
samples or pools were incubated in duplicate in four serial
dilution steps for 2 hours at 37oC. The plates were incubated
with peroxidase-conjugated anti-human IgG or anti-human
IgA (Sigma, St. Louis, MO, USA) for 90 minutes at 37oC, and
the reaction was developed with 0.4 mg orthophenylenedia-
mine/ml (Sigma, St. Louis, MO, USA) and read at 492 nm. The
plates were washed with PBS–0.1% Tween between each step.
The anti-Sa IgG and IgA concentrations were expressed as
arbitrary units (AU/ml) that were obtained by a comparison to
the OD values of the serum or colostrum pool, both defined to
contain 1000 AU/ml of anti-Sa IgG or IgA, respectively.
Serum anti-S. aureus IgG1 and IgG2 subclasses
The microplates were adsorbed with S. aureus as described
above. After blocking, the paired maternal and umbilical
cord serum samples were added in duplicate at four serial
dilution steps for 2 hours at 37oC. Biotinylated anti-human
IgG1 (555869; BD Pharmingen, San Diego, CA, USA) or IgG2
(555874; BD Pharmingen, San Diego, CA, USA) was used as
the secondary antibody, both at dilutions of 1:500, and
incubated for 90 minutes. This step was followed by
incubation with streptavidin-HRP (554066; BD Pharmingen,
San Diego, CA, USA) diluted 1:500 for 90 min. The reaction
was completed as previously described. The anti-Sa IgG1
and IgG2 titers were determined as the reciprocal of the
sample dilution corresponding to an OD of 0.5. We expressed
the anti-Sa IgG subclass results in titers because it allowed us
to compare the results of IgG1 with IgG2 for each sample.
Anti-S. aureus IgG and IgA antibody avidity indexes
The avidities of the anti-Sa IgG and IgA antibodies in
the maternal and umbilical cord sera and in the maternal
colostrum samples were determined by elution with differ-
ent molarities (M) of potassium thiocyanate (0.0–4.0 M)
according to the technique described by Jones et al. (14).
The results were expressed as the molarity of potassium
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thiocyanate necessary to elute 50% of the bound antigen-
antibody complexes.
Statistical analysis
The statistical analyses were performed using GraphPad
Prism version 5.0 for Windows (GraphPad Software, San
Diego, CA, USA). The significance of the differences between
two medians was analyzed using the Wilcoxon signed
rank test for related data and the Mann–Whitney test for
unrelated data. The significance of the differences between
two means was analyzed using the unpaired t-test. The anti-
Sa IgG, IgG1 and IgG2 antibodies were compared between
the maternal and umbilical cord sera using the Spearman
correlation coefficient. The significance level was set at
po0.05 for all analyses. The placental transfer ratios of the
total and specific antibodies were defined in each assay as
the ratio of the umbilical cord concentrations/maternal
concentrations x 100.
’ RESULTS
Characteristics of the study population
Of the 250 parturients selected for this study, 49 were
nasally colonized with S. aureus and were included in the
case group (prevalence of 19.6%). Two hundred and one
(80.4%) had negative nasal cultures; of these, we included
98 women, who comprised the control group. The demographic
characteristics of the two groups are summarized in Table 1.
Total IgG concentrations and placental transfer
ratios
The descriptive statistical analysis is summarized in Table 2.
The maternal sera from the case group had significantly
higher IgG concentrations than the maternal sera from the
control group. No statistically significant differences were
detected in the medians between the umbilical cord serum
samples from the case and control groups. The total IgG
concentrations in the umbilical cord serum samples from the
control group were higher than those in the serum samples
from their respective mothers. A significantly lower placental
transmission of the total IgG antibodies was detected in the
case group than in the control group.
Anti-S. aureus IgG concentrations and placental
transfer ratios
The Wilcoxon analyses demonstrated significantly lower
anti-Sa IgG concentrations in the umbilical cord serum
samples from the newborns of the case and control groups
than those observed in their respective mothers. The Mann-
Whitney analyses revealed no significant differences in
the anti-Sa IgG concentrations between the mothers and
between the umbilical cord serum samples from the case
and control groups. The anti-Sa IgG transfer ratio was
significantly lower in the case group than in the control
group (Table 2).
The Spearman correlation analysis revealed high correla-
tion indexes of anti-Sa IgG between the paired maternal and
newborn sera in the case group (r=0.964, po0.00001) and
control group (r=0.885, po0.00001).
Anti-S. aureus IgG1 and IgG2 titers and placental
transfer ratios
The Wilcoxon analyses demonstrated significantly higher
anti-Sa IgG1 titers in newborns from the case and control
groups than those observed in their respective mothers
(po0.0001), whereas the analysis of anti-Sa IgG2 showed
lower levels in the newborns from both groups than in their
mothers (po0.0001) (Figure 1a and 1d). When the maternal
sera from the case group and the control group were
compared, no differences were detected in the anti-Sa IgG1
or anti-Sa IgG2 titers. The same result was observed between
the newborns from both groups (Figure 1a and 1d).
As revealed by the Wilcoxon analyses, the comparison of
the anti-Sa IgG1 and IgG2 titers showed significantly higher
IgG2 titers than anti-Sa IgG1 levels in both the maternal and
umbilical cord sera from both groups (po0.0001).
The Spearman correlation analysis revealed high correla-
tion indexes of anti-Sa IgG1 and anti-Sa IgG2 between the
paired maternal and newborn serum in both groups
(po0.00001) (Figure 1b, c, e and f).
Interestingly, in the case group, the Spearman analysis
showed a significant correlation index between the maternal
anti-Sa IgG levels and the neonatal anti-Sa IgG2 titers
(r=0.601, po0.00001), and the opposite was also observed,
wherein the maternal anti-Sa IgG2 titers were correlated with
the neonatal anti-Sa IgG levels (r=0.544, po0.00001). The
same result was observed in the control group when the
maternal anti-Sa IgG levels and the neonatal anti-Sa IgG2
titers were compared (r=0.343, po0.001) and when the
maternal anti-Sa IgG2 titers and the neonatal anti-Sa IgG
levels were compared (r=0.364, po0.001). Neither the
maternal nor neonatal anti-Sa IgG1 titers were correlated
with the anti-Sa IgG levels or the anti-Sa IgG2 titers in either
group.
No statistically significant differences were detected in
the medians of the anti-Sa IgG1 placental transfer ratios
between the case and control groups or when the placen-
tal transfer ratios of anti-Sa IgG2 were analyzed. Alter-
natively, the case and control groups revealed significantly
higher anti-Sa IgG1 placental transfer ratios than IgG2
(Figure 2).
Table 1 - Demographic and obstetric characteristics of the parturients (n=147) according to their nasal S. aureus carrier status, Cuiaba´-MT.
S. aureus nasal carrier status
Case Group
(n=49)
Control Group
(n=98)
p value
Maternal age in years (median) 23 24 0.3681
Gestational age in weeks (mean) 39.1 39.1 0.7942
Primiparous (n; %) 9; 18.4% 35; 35.7% 0.0312
Weight at birth in grams (mean) 3305.0 3275.1 0.6575
Placental weight in grams (mean) 635.1 643.8 0.7035
Number of cotyledons in each placenta (mean) 10.1 10.2 0.7093
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Total and anti-S. aureus IgA concentrations
in the colostrum
Although all of the colostrum samples were collected
approximately 24 hours post-partum (range=17.5 - 24.6
hours), the total IgA in the colostra had a large range of
variation. Significantly higher total IgA concentrations were
observed in the colostrum samples from the case group than
in those from the control group (po0.05). The Sa-specific IgA
concentrations in the maternal colostrum were equivalent
between the groups (Table 3).
Avidity indexes of anti-S. aureus IgG and IgA
In both the case and control groups, the avidity indexes
of the anti-Sa IgG antibodies did not differ between the
maternal and umbilical cord serum samples. The same result
was observed for the avidity indexes of anti-Sa IgA in the
colostrum samples, which did not show differences between
the case and control groups (Table 4).
’ DISCUSSION
The present study revealed similar concentrations of anti-
staphylococcal IgG antibodies in the sera of mothers with
and without bacterial nasal carriage, suggesting that maternal
anti-Sa IgG antibodies are not related to colonization with this
pathogen. The same effect was observed in the avidity indexes
of anti-Sa IgG between the maternal or neonatal sera from the
case and control groups and between the paired maternal and
cord sera. Avidity and antibody specificity are determined by
the Fab’ fragment of IgG, while placental transfer is Fc-related;
therefore, it was unexpected that antibody avidity could be
different between the mother/newborn pairs (15).
S. aureus becomes part of the host microbiota within the
first hours of life (16), which allows healthy individuals to
have high specific antibody levels independent of nasal
colonization at the time of measurement (17). Furthermore,
anti-staphylococcal IgG and IgA levels and Sa antigenic
diversity show great individual variability in healthy
individuals and in the presence of bacteremia (17,18). This
variability has been attributed to strain characteristics, with
strain-specific arsenals of evasion mechanisms and differ-
ences in the host immune response to this bacterium (19).
In the present study, the placental transfer of total IgG
agrees with the current literature that describes positive IgG
placental transfer ratios for newborns in healthy full-term
pregnancies. However, when the mother has a high content
of total IgG or of a specific antibody, the neonatal value
usually remains below the maternal value due to the amount
of cell surface receptors, and a lower placental transfer ratio
is a result of the digestion of unbound IgG molecules by
lysosomal enzymes within vesicles (20,21).
The finding that both groups had lower placental transfer
ratios of anti-staphylococcal antibodies than expected in an
assay performed with whole bacteria prompted us to
evaluate specific IgG subclasses. Several studies have demo-
nstrated that the immune response in adults is composed of
antibodies reactive to antigenic determinants of bacterial
surfaces related to different stages of Sa pathogenesis; never-
theless, the highest levels of neutralizing antibodies are
predominantly directed to non-protein antigens (17,22).
The higher anti-Sa IgG2 than IgG1 titers in maternal and
neonatal sera in both groups was unexpected because it is
well known that preferential placental transport occurs for
IgG1, followed by IgG4, IgG3 and IgG2, for which the FcRn
receptors have the lowest affinity (23). In our study, to
compare the anti-staphylococcal IgG1 results with those of
IgG2 in each sample, the assays were performed under the
same conditions, and the subclass results were expressed in
titers. As expected, the placental transfer ratio of anti-Sa IgG1
was higher than that of IgG2. However, as the maternal
anti-staphylococcal IgG1 titers were much lower than those
of IgG2, the anti-Sa IgG2 titers in neonatal serum were
markedly higher than those of IgG1. The predominance of
anti-Sa IgG2 over IgG1 in the maternal sera could explain the
lower placental transfer ratio observed for IgG anti-Sa in
both the case and control groups. This idea was further
reinforced by the significant correlation indexes revealed
when the maternal serum anti-Sa IgG and neonatal serum
anti-Sa IgG2 were compared and vice-versa. A study with
children with and without otitis media who were vaccinated
Table 2 - Total IgG, S. aureus-specific IgG antibodies and placental IgG transfer ratios in the maternal and umbilical cord serum samples
from the case (n=45) and control (n=98) groups.
Total IgG (mg/dL)
Case Group Control Group p value
Maternal Serum 1069.0
[991.0-1116.0]
939.0*
[907.0-996.0]
po0.01
Cord Serum 1034.0
[1027.0-1138.0]
1041.0*
[1044.0-1146.0]
Cord/Maternal Ratio (%) 100.9
[98.9-112.6]
114.1
[112.6-125.9]
po0.05
Anti-S. aureus IgG (AU/mL)
Case Group Control Group p value
Maternal Serum 317.0w
[366.6-678.8]
317.4w
[409.4-579.9]
Cord Serum 224.7w
[243.3-453.8]
264.7w
[308.4-429.2]
Cord/Maternal Ratio (%) 69.5
[65.5-76.3]
81.3
[77.3-90.1]
po0.05
The values represent median and confidence intervals (95%).
*Higher total IgG concentrations in the newborns from the control group compared with their respective mothers (po0.0001).
w Lower anti-Sa IgG concentrations in the newborns from the case and control groups than observed in their respective mothers (po0.0001).
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Figure 1 - Anti-S. aureus IgG1 and IgG2 titers in paired maternal and cord serum samples from the case and control groups. (a) Anti-
S. aureus IgG1 titers and (d) anti-S. aureus IgG2 titers in the maternal serum and umbilical cord serum samples from the case (n=48) and
control group (n=98). In (b) and (c), correlation coefficients between paired maternal and umbilical cord serum of anti-Sa IgG1 in the
case and control group, respectively. In (e) and (f), correlation coefficients between the paired maternal and umbilical cord serum of
anti-Sa IgG2 in the case and control group, respectively. In (a) and (d), the box represents the 25th–75thpercentiles, and the median is
represented by the line within the box. The whiskers represent the 5th–95th percentiles.
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with Streptococcus pneumoniae, another Gram-positive bacter-
ium, showed no differences between groups, and strong
correlations were demonstrated between anti-PCP (capsular
antigen of S. pneumoniae) IgG and the anti-PCP IgG2, as
observed in our study (24).
In a study that correlated the protective immune response
to a conjugated pneumococcal vaccine, high levels of speci-
fic IgG, IgG1 and IgG2 were found, and both IgG subclas-
ses correlated significantly with the opsonophagocytic
activity. No significant increases were found in the mean
antibody avidities, which were already high in the pre-
vaccination samples (25). However, they revealed that neu-
tralization of antibodies directed to the cell wall polysac-
charide had no influence on the opsonophagocytic activity
of the sera. It has been reported that anti-pneumococcal
cell wall polysaccharide antibodies have very little opsonic
activity (26).
It is well known that complement poorly lyses the plasma
membranes of Gram-positive bacteria because of their
thick peptidoglycan layers (27). Thus, it has been argued that
antibody-mediated opsonophagocytic bacterial killing is neces-
sary to increase the bactericidal efficiency of MAC against
Gram-positive bacteria (28). IgM antibodies and IgG1 and IgG3
subclasses are known to effectively act in these processes,
whereas IgG2 shows a much weaker ability. According to our
results, this could be an additional limiting factor for newborns
to cope with these bacteria (29).
Vaccine trials using the Sa capsular polysaccharide 5 and
8 conjugate vaccine revealed that, despite a substantial rise
in the post-vaccination anti-CP5 and anti-CP8 antibody con-
centrations, the Sa nasal colonization rates did not signifi-
cantly change (30).
These results highlight the importance of therapeutic strategies
to address Gram-positive bacteria using the induction of
Figure 2 - Placental transfer ratios (%) of anti-S. aureus IgG1 and IgG2 from case and control groups. Comparison of the data is
presented as box and whisker plots. The box represents the 25th–75th percentiles, and the median is represented by the line within the
box. The whiskers represent the 5th–95th percentiles.
Table 3 - Total and S. aureus-specific IgA antibodies in the maternal colostrum samples from the case (n=45) and control (n=98) groups.
Case Group Control Group p value
Total IgA (g/L) 163.3
[152.2 - 216.2]
125.7
[125.8 - 158.3]
po0.05
Anti-S. aureus IgA (AU/mL) 4019.0
[3747.0 - 7024.0]
5337.0
[6048.0 - 12423.0]
The values represent median and confidence intervals (95%).
Table 4 - Avidity indexes of anti-S. aureus (Sa) IgG in the maternal and umbilical cord serum samples and IgA in the maternal colostrum
from the case (n=17) and control (n=18) groups.
Serum Anti-Sa IgG Avidity Index (M)* Colostrum Anti-Sa IgA Avidity Index (M)
Case Group Control Group Case Group Control Group
Maternal Cord Maternal Cord
Median 1.4 1.3 1.5 1.2 2.5 2.3
Min 0.9 0.9 0.7 0.8 1.3 1.2
Max 3.5 2.9 3.7 3.2 4.0 2.8
CI 95% 1.2-1.9 1.2-1.8 1.3-1.9 1.2-1.9 2.0-2.8 2.0-2.5
* The results were expressed as the molarity (M) of potassium thiocyanate necessary to elute 50% of the bound antigen-antibody complexes.
Min = minimum; Max = maximum; CI 95%= confidence interval 95%.
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immunity by vaccination or passive immunization. These strat-
egies should consider the subclass produced or administered
because IgG1 is the main subclass involved in opsonophago-
cytosis and the interaction of innate and acquired immunity.
Studies aimed at developing vaccines against Sa are still
performed because carriers have more infections, but these
are less severe (31,32), which strongly suggests that some form of
immunity has developed during prolonged colonization. The
rationale for the development of those vaccines is based on
evidence that antibodies directed to toxic shock toxin (33) and
a-hemolysin (Hla) reduce the severity of the disease (34), and
inhibitors of Hla receptor are also protective (35).
In pregnant women, due to the mucosal immune system
and broncoenteromammary axis, secretory IgA produced by
the mother against pathogens that colonize mucous mem-
branes is offered to the newborn through the breast milk.
This occurs because, once in the nasal site, Sa can interact
with the nasopharynx-associated lymphoid tissue (NALT),
and anti-staphylococcal IgA-producing B lymphocytes can
migrate to the mammary gland. The mammary gland then
releases specific IgA in breast milk that may help to prevent
nasal colonization, since the main characteristic of secretory
IgA antibody is to perform immune exclusion by inhibiting
colonization and invasion by pathogens (10).
Kawano and Emori (36) assessed total secretory IgA in
human milk and found higher IgA concentrations in the
colostrum samples at 72 hours post-partum in primiparous
women. In the present study, there were more primiparous
women in the control group, but we found higher total IgA
concentrations in the case group. However, the total IgA
concentrations in the colostrum at 24 hours did not differ
between primiparous and multiparous women.
Because we found no differences in the anti-Sa IgA con-
centrations and avidity indexes between the groups, nasal
colonization was not related to an increase in specific IgA
antibodies or avidity indexes in the colostrum.
In conclusion, this study revealed that, in healthy pregnant
women, nasal colonization by S. aureus at delivery is not
associated with higher specific serum IgG concentrations in
the mother or in newborns or with higher specific secretory
IgA in the colostrum. The high titers of anti-Sa IgG2 found in
the umbilical cord serum suggest a greater reactivity with
non-protein antigens, which may further contribute to the
susceptibility to staphylococcal infections at birth. Because
newborns are early exposed to S. aureus the detection of
specific IgA with avidity for this pathogen in the colostrum
reinforces the importance of encouraging breastfeeding
shortly after birth.
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